ATH

Alpha Sigma Capital Research Releases April Report on ASC AI Index

Retrieved on: 
星期四, 五月 9, 2024
ASC, AAI, ASCR, Index, ATH, AI

Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).

Key Points: 
  • Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).
  • AAI tracks the price performance of the top tokens in the AI sector, using a rules-based criteria designed to reflect the landscape of AI tokens.
  • The index includes the top 30 tokens that meet the minimum criteria of market capitalization, daily trading volume, and quality of exchange venues.
  • To receive monthly reports on ASC AI Index to your inbox, subscribe to alphasigmacapitalresearch.substack.com.

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
星期三, 五月 8, 2024
Neurodegenerative disease, Neuroimaging, MSA, Safety, Pharmacokinetics, Food, ASX, Pathology, Disease, Data monitoring committee, Patient, DMC, Biomarker, Clinical trial, Therapy, ATH, Food and Drug Administration, SAN, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

Cloudbench and Arhasi have announced a mutual investment in each other, deepening their AI partnership

Retrieved on: 
星期二, 五月 7, 2024
Ecosystem, Machine learning, Partnership, Artificial intelligence, Engineering, ATH, Sales

The decision to strengthen the partnership underscores the joint commitment to provide enhanced services to clients implementing AI initiatives, coinciding with a surge in demand for AI services.

Key Points: 
  • The decision to strengthen the partnership underscores the joint commitment to provide enhanced services to clients implementing AI initiatives, coinciding with a surge in demand for AI services.
  • "It's been an extraordinary beginning to the year for Cloudbench, marked by launching ourselves as a top AI and Web3-focused Google partner and establishing a deeper strategic partnership with Arhasi through our mutual investment”, said Tom Richer , Founder of Cloudbench.
  • "Since its launch, Cloudbench has focused on emerging technology, assisting startups and midmarket clients across diverse sectors in unlocking the full potential of AI.
  • Cloudbench and Arhasi are well poised to spearhead this future, actively shaping and enabling its evolution.”

Powerledger and MYTILINEOS Collaborate for Clean Energy PPA Tracking and Smart Sourcing

Retrieved on: 
星期三, 四月 17, 2024
GOS, RIC, AI, Kilowatt-hour, Blockchain, Power purchase agreement, Partnership, Professional, Carbon, EV, OTC Markets Group, MYTIL, ATH, Cryptocurrency

Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.

Key Points: 
  • Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.
  • Zug, Switzerland--(Newsfile Corp. - April 17, 2024) - Powerledger in partnership with MYTILINEOS Energy & Metals (RIC: MYTr.AT) (ATH: MYTIL) (OTC Pink: MYTHY) (MYTILINEOS) through Protergia , introduces energy provenance tracking and tracing solutions in Greece.
  • Powerledger - MYTILINEOS partnership boasts several key features as following:
    It allows consumers to trace, visualise near real-time energy using blockchain and AI.
  • "The Powerledger blockchain meticulously tracks and traces the supplied energy from its generation source to its point of consumption, from smart meter data.

$BENJI Token Sets New Standards on Base Chain with $30 Million Market Cap in 24 Hours

Retrieved on: 
星期三, 四月 10, 2024
Binance, ATH, Social media, Cryptocurrency

New York, New York--(Newsfile Corp. - April 10, 2024) - Basaenji's token $BENJI achieved new heights after surging to a $30 million market cap in the first 24 hours.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 10, 2024) - Basaenji's token $BENJI achieved new heights after surging to a $30 million market cap in the first 24 hours.
  • $BENJI, the brand new addition to the Base Chain surroundings, has emerged as a premiere token with an unprecedented surge to $30 million market cap on the first day.
  • $BENJI's market cap rose to an impressive $30 million within the first 24 hours of its launch, and an ATH of 57M in its first week stands as a testament to the power of network-backed projects.
  • With unwavering dedication to excellence, BENJI has set up itself as a pioneer in branding and network outreach.

BADMAD ROBOTS Announces Listing on Epic Games Store and Steam, Teams Up with Immutable X

Retrieved on: 
星期四, 四月 25, 2024
Elixir, Dark, Circle, Binance, 2000s, News, Q2, OKX, Blockchain, Partnership, Ubisoft, Ultra, Dying Light 2, Call, Unreal Engine, Steam, Animoca Brands, METAL, YGG, ATH, Revolution, Video game

Singapore, April 25, 2024 (GLOBE NEWSWIRE) -- BADMAD ROBOTS , a team-based multiplayer shooter game, announced its official listing on Epic Games Store and Steam , two of the most prominent gaming distribution platforms worldwide.

Key Points: 
  • Singapore, April 25, 2024 (GLOBE NEWSWIRE) -- BADMAD ROBOTS , a team-based multiplayer shooter game, announced its official listing on Epic Games Store and Steam , two of the most prominent gaming distribution platforms worldwide.
  • Moreover, BADMAD ROBOTS has confirmed the industry’s support after signing an exclusive partnership with Immutable X for the game’s launch.
  • Immutable X is also the partner of major industry brands, including OKx, Ubisoft, and others.
  • Recently, BADMAD ROBOTS announced the support and collaboration of 12 famous esports teams, which have amassed over 9 million followers worldwide.

Coinstore New Public Chain Forum “Finding the Future Alpha” Has Completed Successfully

Retrieved on: 
星期一, 四月 22, 2024
XRP, Cardano, VCS, MSB, CMO, DFG, Nifedipine, ETF, Ecosystem, Capital, Telco, Conflux, AI, BTC, CEX, RWA, Wi-Fi, Research, SOL, Gold, Roam, BSC, IVC, Optimism, DVT, Logic, ICO, Meme, ATH, AVAX, Partner, SSV, Cryptocurrency

Singapore, April 22, 2024 (GLOBE NEWSWIRE) -- Global top crypto asset platform, Coinstore, held a new public chain forum called “Finding the Future Alpha - Will Solana lead the next boom? ''

Key Points: 
  • Singapore, April 22, 2024 (GLOBE NEWSWIRE) -- Global top crypto asset platform, Coinstore, held a new public chain forum called “Finding the Future Alpha - Will Solana lead the next boom? ''
  • Before the forum, Coinstore has rich experience in holding events,and has actively published Cryptalk and CS Connect events.To date, Coinstore held more than 30 Cryptalk, nearly 40 CS Connect and 22 Expo conferences.
  • This public chain forum will become a benchmark forum.
  • Coinstore will hold more forums and events in the future to promote the collision of technology, capital, and new ideas, and bring innovation to the crypto industry.

Patrick Martin, GP, Alpha Transform Holdings, Presenting at Global Blockchain Congress in Dubai

Retrieved on: 
星期一, 四月 22, 2024
Crypto, Blockchain, Investment, ATH, Initial public offering, General partnership, AI, Cryptocurrency

London, U.K., April 22, 2024 (GLOBE NEWSWIRE) -- Patrick Martin , General Partner, Europe for Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, will present at the Global Blockchain Congress in Dubai on April 25th.

Key Points: 
  • London, U.K., April 22, 2024 (GLOBE NEWSWIRE) -- Patrick Martin , General Partner, Europe for Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, will present at the Global Blockchain Congress in Dubai on April 25th.
  • Mr. Martin will present on the Crossroad Between AI and Crypto.
  • The disruptiveness of AI has made it a force to be reckoned with.
  • He is a frequent speaker and industry specialist on all things fintech, Web3, and blockchain.

Alpha Transform Holdings Releases March Report on ASC AI Index

Retrieved on: 
星期四, 四月 18, 2024
ASC, AAI, Index, ATH, AI

Tampa, FL, April 18, 2024 (GLOBE NEWSWIRE) -- Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the March report on ASC AI Index (AAI).

Key Points: 
  • Tampa, FL, April 18, 2024 (GLOBE NEWSWIRE) -- Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the March report on ASC AI Index (AAI).
  • AAI tracks the price performance of the top tokens in the AI sector, using a rules-based criteria designed to reflect the landscape of AI tokens.
  • The index includes the top 30 tokens that meet the minimum criteria of market capitalization, daily trading volume, and quality of exchange venues.
  • To receive monthly reports on ASC AI Index to your inbox, subscribe to alphasigmacapitalresearch.substack.com.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
星期三, 四月 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.